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Abstract 
Objective. To study the efficiency of using carbamylated darbepoetin, asialized erythropoietin and an 11-amino acid peptide that simulating 
the spatial structure of the B-erythropoietin alpha-helix in the correction of L-NAME-induced nitric oxide deficiency in the late gestation 
period. 
Methods. The experiment was performed on 100 female white rats of Wistar strain weighing 250-300 g. Carbamylated  darbepoetin 
(Pharmapark LLC) in a dose of 50μg/kg and 300 μg/kg was administered subcutaneously 1 time per each 7, 10, 13, 16, 19 days of pregnancy. 
Asialized erythropoetin in doses of 0.4μg/kg and 2.4μg/kg was also administered subcutaneously 1 time a day from the 10th to the 20th days 
of pregnancy. A peptide imitating the α-helix of B-erythropoietin (P-αB) was administered at a dose of 50 μg / kg ip 1 day / day from 10 to 20 
days of pregnancy. On the 21st day of pregnancy, functional tests and laboratory examination were conducted. 
Results. Administration of carbamylated darbepoetin, asialiated erythropoetin and peptide that imitating the α-helix of B-erythropoietin in 
animals causes the expressed correction of pathological changes in experimental L-NAME induced preeclampsia with the highest effect in a 
higher dose of the test drug. There was a significant rise in systolic and diastolic blood pressure, respectively, the improvement of 
microcirculation in the placenta, restoration of endothelium NO-synthesis function, proteinuria reduction. The most effective decrease in 
blood pressure and its maximum approximation to the target figures for SBP and DBP in intact animals was found in the group of animals 
treated with a рeptide imitatimg the α-helix of B-erythropoietin (P-αB). 
Conclusion. The results of the study indicate the promise of using a erythropoietin derivatives and peptide that imitate the α-helix of B-
erythropoietin with L-NAME-induced nitric oxide deficiency in the late gestation period and justifies the feasibility of further studies in this 
direction. 
 
Key words: peptide that imitate the a-helix of B-erythropoietin, erythropoietin derivatives, L-NAME induced endothelial dysfunction, rats, 
microcirculation, late gestation, preeclampsia. 
 
© 2019 by Advance Scientific Research. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ ) DOI: 
http://dx.doi.org/10.22159/jcr.06.06.24   
 
Introduction 
For the time being, preeclampsia remains one of the most 
serious multisystem pathological complications of pregnancy. 
Maternal mortality reaches 30% . Over 40 theories of 
preeclampsia etiology and pathogenesis exist so far. No 
unified theory exists that would allow covering and 
explaining the entire set of pathological processes occurring 
in a body of a pregnant woman who has this pathology. 
Recently, much attention in preeclampsia pathogenesis has 
been paid to endothelium functional condition changes. 
Modern studies of the endothelium functional condition at 
preeclampsia focus on the endothelial vasorelaxation factor 
represented by nitrogen monoxide (NO), which is synthesized 
in the body in response to the physiological need from L-
arginine amino acid affected by NO-synthase (NOS) enzyme. 
Nitrogen monoxide is the most powerful of all endogenous 
vasodilators known. A normally functioning endothelium is 
characterized by permanent basal NO production which is 
required for normal basal vascular tone maintenance [1, 14]. 
Since NO regulates vascular tone, including that of resistive 
vessels, the decrease in its synthesis or bioavailability leads 
to vasoconstriction and the peripheral vascular resistance 
increase. At the same time, NO mediates dilatation of renal 
vessels and controls the kidney function, especially the 
mechanisms of sodium excretion from the body. Thus, the 
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weakening of these NO-dependent mechanisms contributes to 
hypertension development [2, 15]. NO produced under the 
action of eNOS doesn’t only takes part in vascular tone and 
blood pressure regulation; it also performs the following 
important functions: inhibits PT adhesion, activation, 
secretion and aggregation, and WBC adhesion to the 
endothelium [3, 16], inhibits the release of mitogens from PT; 
regulates the formation of endothelin-1 and platelet-
activating factor by endotheliocytes; inhibits migration and 
proliferation of vascular smooth muscle cells; regulates the 
angiotensin-2 biological action, etc. 
For the time being, system pleiotropic protective effects of 
erythropoetin in the conditions of its intensified production 
were determined. According to reference data, EPO increases 
the duration of functioning of endothelium cells at oxygen 
starvation, has antiapoptotic effect in relation to endothelium 
cells, cause activation of endothelial NO-synthase and 
prevents vasomotor spasm, decreases NO-toxicity and has the 
direct antioxidant effect [4]. The EPO cytoprotective activity 
realization is mediated by binding with EPOR-βCR 
heterodimeric receptor, which, in its turn, causes the 
decrease of cell sensitivity to hypoxia and activation of 
antiapoptotic signalic pathways. The number of studies 
demonstrated that EPU hybrid variants, modified under 
amino acid residual of high- and low-affinity sites of binding 
with EPOR preserve their cytoprotective properties [5, 6, 14]. 
“Non-classic” EPO activity allows considering it as a 
therapeutic agent for preventing conditions associated with 
necrosis, apoptosis and inflammatory process in tissues, in 
particular, in preeclampsia therapy. However, erythropoetic 
activity may cause undesirable adverse effects. This 
contradiction led to the attempts to create modified EPO that 
would preserve their cytoprotective properties at the 
absence of blood-forming action. One of such modifications 
became carbamylation causing both the molecular structure 
and function of ЕРО change [5]. We used carbamylated 
darbepoetin (Pharmapark LLC) in our study.  
Moreover, one of the directions of the “erythropoetic” defect 
removal is creating erythropoetin derivatives with the short 
life cycle. In order to activate cytoprotective effects,  it is 
sufficient for erythropoietin to bind with heterodimeric 
receptor for the short period of time (5 minutes). For 
erythropoesis activation, it is erythropoetin should stay on 
the homodimeric receptor permanently for a long time. In our 
study, we used asialiated erythropoietin purified from EPO 
form sialic acids (Proteinovy Kontur LLC).  
As the most promising derivative of erythropoietin with 
endothelial and cytoprotective activity, we selected an 11-
amino acid peptide that imitate the spatial structure of the B 
erythropoietin alpha-helix. We obtained the specified 
derivative of erythropoietin under the laboratory code P-αB 
having the following amino acid sequence - Pyr-Glu-Gln-Leu-
Glu-Arg-Ala-Leu-Asn-Ser-Ser. 
The goal is to investigate the effectiveness of the use of 
carbamylated darbepoetin, asialized erythropoietin and an 
11-amino acid peptide that imitate the spatial structure of the 
erythropoietin B alpha-helix in correcting L-NAME-induced 
nitric oxide deficiency in the late gestation period.  
The study was supported by the Ministry of Science and 
Higher Education of the Russian Federation (subsidy 
agreement No. 05.605.21.0191, the unique identifier of the 
agreement is RFMEFI60519X0191). 
 
Methods 
The study was carried out in the Center for Clinical and Pre-
Clinical Studies of FSAEI HE ‘BSNRU’. The experiment was 
carried out in accordance with legislative acts and 
regulations governing the conduct of experimental studies in 
the Russian Federation: (Order of the Ministry of Health of 
Russia N199n of 01.04.2016 “On approval of the Rules of 
Good Laboratory Practice”, GOST 33044-2014 “Principles of 
Good Laboratory Practice”, GOST  33217-2014 “Regulations 
for management the management and the treatment of 
laboratory animals. Rules for the management and the 
treatment of laboratory mammals”, “Regulations for the 
conduct of pre-clinical studies of new medicinal drugs” edited 
by Mironov A. N., 2012.). Ethical principles for the treatment 
of laboratory animals met “European Convention for the 
Protection of Vertebral Animals Used for Experimental and 
Other Scientific Purposes. CETS N170.”  
The experiment was performed on 140 female white rats of 
Wistar strain weighing 250-300 g. Pregnant rats were divided 
into 8 groups: Group 1 – intact; group 2 - control (L-NAME 
administration); group 3 - L-NAME + carbamylated 
darbepoetin (50 μg / kg); group 4 - L-NAME + carbamylated 
darbepoetin (300 μg / kg); group 5 - L-NAME + asialized 
erythropoietin (0.4 μg / kg); group 6 L-NAME + asialized 
erythropoietin (2.4 μg / kg); group 7 - L-NAME + peptide that 
imitate the α-helix of B-erythropoietin ( P-αB) (50 μg / kg); 
group 8 - subcutaneous administration of erythropoietin at a 
dosage of 50 IU / kg.. 
ADMA-like agent - non-selective NO-synthase blocker of N-
nitro-L-arginine methyl ester (L-NAME) was administered 
intraperitoneally in a dose of 25 mg/kg/daily for seven days 
(day 14-20 of pregnancy) [7, 8]. Carbamylated  darbepoetin 
in a dose of 50μg/kg and 300 μg/kg was administered 
subcutaneously 1 time a day on 7, 10, 13, 16, 19 days of 
pregahncy to the animals of 3 and 4 groups. Asialiated 
erythropoietin was also administered subcutaneously for the 
period from the 10th to the 20th day of pregnancy in doses of 
0.4 μg/kg and 2.4 μg/kg to 5 and 6 groups of pregnant rats, 
respectively. The peptide (P-αB) imitating the α-helix of B-
erythropoietin (50 μg / kg) was administered 
intraperitoneally from 10 to 20 days of pregnancy. On the 21st 
day of pregnancy, a laboratory animal was anesthetized by 
intraperitoneal injection of chloral hydrate in a dose of 300 
мг/kg from body weight, after which, functional tests 
followed [9].  
The degree of endothelial dysfunction in experimental 
animals was assessed by the ratio of endothelium-dependent 
vasodilation and endothelium-independent vasodilation with 
the subsequent calculation of coefficient of endothelial 
dysfunction (CED) [10, 22]. 
The NO metabolite level was detected by colorimetric 
method. 
In order to obtain data about the condition of 
microcirculation in the placenta for the 21st day of pregnancy, 
microcirculation level at a distance of 1 mm from the 
placental disc edge [11] was measured with anesthesia.  
The descriptive statistics was applied for all data: data were 
verified for normality of distribution. The distribution type is 
determined by Shapiro-Wilk W test. In the case of normal 
distribution, the mean (M) and standard error of the mean 
(m) were calculated.   The inter-group discrepancies were 
characterized by parametric (Student’s t-test) or non-
parametric (Mann–Whitney U test) methods, depending on 
the distribution type. 
 
Study results 
After the administration of L-NAME in pregnant rats, the 
blood pressure increase occurred: SBP was 194.8±7.88 mm 
Hg, DBP was 149.8±4.73 mm Hg, while in intact animals, 
systolic and diastolic pressure parameters were 132.30±3.46 
and 92.40±3.87 mm Hg, respectively.  
When a peptide (P-αB) imitating the α-helix of B-
erythropoietin (50 μg / kg) was administered during the 
period from 10 to 20 days of pregnancy, a statistically 
significant (p <0.05) compared to the group of “untreated” 
animals occurred a decrease in systolic and diastolic blood 
pressure to 142.80 ± 1.98 and 90.40 ± 5.21 mm Hg, 
respectively. 
In the group of animals with the reference drug, 
erythropoetin, the decrease in systolic and diastolic pressure 
to 173.5±3.66 mm Hg and 130.9±4.38 mm Hg, respectively, 
was observed.  
The administration of asialiated erythropoetin also led to the 
significant (p <0.05) SBP decrease to 183.1±6.71 (in a dose of 
0.4μg/kg) and 167.3±3.43 (2.4μg/kg). For diastolic BP, after 
asialiated erythropoetin administration, these parameters 
were 139.7±3.72 and 129.4±4.17 respectively. After the 
administration of carbamylated darbepoetin in a dose of 
50μg/kg and 300 μg/kg per day, a significant decrease in 
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systolic BP to 189.10±6.49 mm Hg and 168.20±6.56 mm Hg, 
and in diastolic BP up to 144.00±3.48 mm Hg and 
125.80±3.50 mm Hg, respectively, was observed (Table 1).  
The administration of L-NAME in pregnant rats caused 
violation of vascular tone regulatory mechanisms, proved by 
CED increase from 1.20±0.07 to 3.17±0.22.  
The introduction of erythropoietin and its derivatives led to 
the normalization of vascular reactions of endothelium-
dependent and endothelium-independent vasodilation 
statistically significantly lowering the QED indicators to 1.95 
± 0.19, however, these values did not reach the target. The 
introduction of a peptide (P-αB) imitating the α-helix of B-
erythropoietin (50 μg / kg) during the period from 10 to 20 
days of pregnancy intraperitoneally led to a statistically 
significant (p <0.05) compared with the group of “untreated” 
animals decrease in QED to 2.0 ± 0.06. 
Course administration of carbamylated darbepoetin in doses 
of 50 μg/kg and 300 μg/kg to pregnant animals with ADMA-
like preeclampsia reduced the CED to 2.19±0.22 and 
1.44±0.18, which proves the endothelial function 
improvement.  
In the animals with ADMA-like preeclampsia, 
microcirculation decrease from 465.9 ± 28.79PU to 211.8 ± 
6.03 PU was observed. Аdministration of a peptide (P-αB) 
that simulates the α-helix of B-erythropoietin (50 μg / kg) 
during the period from 10 to 20 days of gestation 
intraperitoneally occurred statistically significant (p <0.05) 
compared with the group of "untreated" animals 
microcirculation in the placenta up to 343.2 ± 5.98.  
The administration of carbamylated darbepoetin in test doses 
recovered microcirculation to 347.6±15.07 PU and 415.9 ± 
20.59 PU, respectively. In groups of animals with the course 
administration of asialiated erythropoetin, these indicators 
recovered to 357.3 ± 22.6 PU and 413 ± 20.0 PU, in relation to 
lower and higher doses. These values exceed the results of 
microcirculation correction with erythropoetin, for which 
these values were 313.4 ± 15.87 PU. 
 
 
Table 1. The impact of P-αB, carbamylated darbepoetin and asialiated erythropoietin on BP, CED and microcirculation in the 
placenta at ADMA-like preeclampsia 
 SBP(mm Hg) DBP(mm Hg) CED(conv.); Microcirculation (PU) 
Intact 132.3±3.46* 92.4±3.87* 1.20 ± 0.07* 465.9±28.79* 
control 194.8 ± 7.88# 149.8 ± 4.73# 3.17 ± 0.22# 211.8±6.03# 
Epo 50 IU/kg 173.5 ± 3.66 #* 130.9 ± 4.38# 1.95 ± 0.19 #* 313.4± 15.87 #* 
(P-αB) 50μg/kg 142.80 ± 1.98* 90.40 ± 5.21* 2.0±0.06*# 343.2±5.98*# 
AsEpo  
0.4μg/kg 183.1±6.71* 139.7±3.72*# 2.09±0.14 * 357.3±22.6#* 
2.4μg/kg 167.3±3.43*# 129.4±4.17*# 1.67±0.12*# 413±20.0* 
CEPO 
50μg/kg 189.1 ± 6.49# 144.0± 3.48 # 2.19±0.22*# 347.6±15.07*# 
300μg/kg 168.2±6.56*# 125.8±3.50*# 1.44 ± 0.18* 415.9 ±20.59* 
 
Note: From this point on - SBP, DBP – systolic and diastolic blood 
pressure (mm Hg); CED – the coefficient of endothelial 
dysfunction (conv.); PU – perfusion units; #- р < 0,05 compared 
to the group of intact animals; * – р < 0,05 compared to the 
control group   
The study of the NO-synthesizing function of the endothelium 
was carried out on the basis of the determination of nitrite - 
NOx ions in blood plasma. Modeling of endothelial 
dysfunction led to a decrease in the content of final NOx 
metabolites in blood plasma. The introduction of a peptide 
(P-αB) that mimics the α-helix of B-erythropoietin (50 μg / 
kg) during the period from 10 to 20 days of pregnancy 
intraperitoneally led to a statistically significant (p <0.05) 
compared with the group of "untreated" animals increasing 
the content of final metabolites of blood plasma to 1.59 ± 0.05 
μmol / dL. After the introduction of carbamylated 
darbepoetin in doses of 50 μg / kg and 300 μg / kg (p <0.05), 
the content of nitrite ions (NOx) in the blood plasma in 
animals with ADMA-like preeclampsia increased to 1.64 ± 
0.02 μmol / dL and 1.91 ± 0.03 μmol / dL, respectively, which 
is close to the target values in the group of intact animals 
(2.31 ± 0.04 μmol / dL). With the administration of asialized 
erythropoietin, a similar dose-dependent result was noted, 
the NOx content was 1.49 ± 0.02 μmol / dL and 1.61 ± 0.02 
μmol / dL. 
 
 
Fig. 1. The impact of erythropoietin derivatives on the level of NO metabolites at  L-NAME-induced nitric oxide deficiency 
in the late gestation period 
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Note: #- р < 0,05 compared to the group of intact animals; * – р < 0,05 compared to the control group 
 
Results and discussion 
In morphological examination of the placenta in women 
who had preeclampsia, the researchers indicate at its 
formation violation. This is expressed in the fact of 
incomplete penetration of chorionic villi into mother’s  
spiral arteries. At the same time, the spiral arteries retain 
their layers up to the muscular, causing trophoblast 
ischemia [13]. The response to ischemia is the ejection of a 
large number of humoral factors, the action of which 
ultimately causes endothelial dysfunction development [12, 
13]. In connection with this, it would be logical to assume 
that anti-ischemic medicinal products can have the 
mediated effect on endothelial dysfunction. However, so far, 
the data that preeclampsia develops more frequently in 
women with diseases related to endothelial function 
violation, and a variety of its manifestation clinical variants, 
does not give a precise answer to the question,  ‘What is 
primary, placenta ischemia or endothelial dysfunction.’ But 
it is obvious that endothelial dysfunction and placenta 
ischemia are mutually penetrating components of 
preeclampsia pathogenesis. 
The preeclampsia model selected by us, despite the fact that 
it is caused by the vasoactive ADMA-like substance, has an 
ischemic component as well. Apparently, the placenta 
vessels are the most sensitive to L-NAME [21, 17], which 
causes their spasm and subsequent ischemia up to necrotic 
events [19, 20]. 
The results of the experiments convincingly indicate the 
pronounced positive effects of, erythropoetin derivatives 
and the peptide (P-αB) that imitate the α-helix of B-
erythropoietin in the correction of endothelial dysfunction 
occurring in animals with ADMA-like preeclampsia. Having 
no erythropoesis-stimulating properties, P-αB, 
carbamylated darbepoetin and asialiated erythropoetin 
have strong antioxidant and cytoprotective properties.  
Conclusion 
Administration of carbamylated darbepoetin, asialiated 
erythropoetin and peptide that imitating the α-helix of B-
erythropoietin in animals causes the expressed correction of 
pathological changes in experimental L-NAME induced 
preeclampsia with the highest effect in a higher dose of the 
test drug. There was a significant rise in systolic and diastolic 
blood pressure, respectively, the improvement of 
microcirculation in the placenta, restoration of endothelium 
NO-synthesis function, proteinuria reduction. The most 
effective decrease in blood pressure and its maximum 
approximation to the target figures for SBP and DBP in intact 
animals was found in the group of animals treated with a 
рeptide imitatimg the α-helix of B-erythropoietin (P-αB). 
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